Printer Friendly

CerMed Corporation to Present at Sachs Associates Third Annual European Global Lifescience Forum on February 11, 2010 in Zurich.

MONTEREY, Calif. -- CerMed Corporation, www.cermedcorp.com, an international women's healthcare medical device company that is commercializing three breakthrough products for cervical cancer screening and a women's controlled barrier contraceptive that protects against infection from HIV, will be presenting at the Sachs Associates Third Annual European Global Lifescience Forum on February 11, 2010 at 14:15 Zurich time.

Linda Masterson, President and Chief Operating Officer of CerMed, will be leading the presentation and will discuss CerMed's products which address two major market segments, cervical cancer screening and contraceptive/sexually transmitted disease (STD) prevention.

Ms. Masterson said, "We are excited about the upcoming presentation which will provide us the platform to meet with key players in the health sciences field and introduce CerMed as an emerging company in the women's healthcare arena. This conference also marks the first time CerMed will be presenting before an industry forum, and will provide us the opportunity to review CerMed's product line and our commercialization plans."

"We believe CerMed is the first company to bring a fundamentally different approach to the improvement of women's cervical health. Our first product, CerMap[TM] Cervical Specimen Collection and Mapping System, will be marketed initially in China, where we already have SFDA clearance. We expect to market worldwide later this summer."

"CerMap[TM] can be used as a front end for collection for the standard PAP analysis and will be used in conjunction with our Point of Care Cervical Cancer Screening Test System, as a replacement for the traditional Pap smear. This system is currently under development with Duke University and Innovative Micro Technology," she continued. "The test system is designed as a primary screening system to replace the standard PAP. It is being designed to provide greater sensitivity and specificity than is currently available from the current standard of care. We believe this novel, low cost product can help save the lives of the half-million women who die from cervical cancer each year, generally because of errors in the current methods or lack of access to expensive laboratories and methods."

She continued, "CerMed's second product under development is CerCap[TM] HIV, a barrier contraceptive cervical cap which reduces the risk of infection from HIV. CerCap[TM] is being developed through strategic partnerships with the University of California San Francisco, one of the leading hospitals in the field."

Ms. Masterson concluded, "With life-saving products ready to launch and others under development, we look forward to becoming an important player in women's healthcare."

About CerMed Corporation

CerMed Corporation, www.cermedcorp.com, is a privately owned international women's healthcare company. CerMed is committed to improving the health of women worldwide by developing, manufacturing and marketing quality, high-value added medical products to prevent, diagnose and treat female reproductive system diseases. The Company focuses on two major markets: the cervical cancer screening market, an $18 billion market opportunity, and the market for a women's controlled HIV contraceptive, a $52 billion market opportunity. CerMed is commercializing three innovative products which address significant limitations of currently available methods in these huge markets.

This press release contains forward-looking statements regarding future events and the future performance of CerMed, Corp. that involve risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to completion of the financing, potential need for additional financing, manufacturing scale-up, completion of development for CerCap and the Cervical Cancer Screening Test System.

CerMap and CerCap are trademarks of CerMed Corporation
COPYRIGHT 2010 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 9, 2010
Words:575
Previous Article:The Hon. Isaac Borenstein (Ret.) Joins Denner Pellegrino, LLP.
Next Article:SeraCare Reports First Quarter Fiscal Year 2010 Results.
Topics:


Related Articles
Novotech to Present Benefits of Outsourcing Clinical Trials To Australia; CEO Invited to Speak at Inaugural Sachs Bloomberg CRO Partnering Forum,...
Peter Cimmet joins Arysta LifeScience as Head of Business Development.
Arysta LifeScience Operates Business Under One Global Identity Arvesta, Calliope and Hokko do Brasil Adopt Single Name.
ESBATech CEO to Present at Sachs Associates 5th Annual North American Forum.
Nventa to Present at Upcoming Investor Conferences.
Chronic Lung Disease - Axentis Pharma Attracts Investment Interest.
James J. Schiro Nominated for Election to Goldman Sachs Board.
Arysta LifeScience Corporation Adds Novel, Plant-Oil Based Insecticide to Its Product Portfolio.
Arysta LifeScience Corporation Names Wayne Hewett COO.
CytRx to Present at the Sachs Associates Annual Biotech in Europe Investor Forum.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters